JOHN ABALLI - 08 Dec 2022 Form 4 Insider Report for EXAGEN INC. (XGN)

Role: President and CEO, Director
Signature: /s/ Kamal Adawi, as attorney-in-fact
Issuer symbol: XGN
Transactions as of: 08 Dec 2022
Net transactions value: +$241,200
Form type: 4
Filing time: 09 Dec 2022, 08:00:22 UTC
Previous filing: 18 Oct 2022
Next filing: 06 Sep 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XGN	Common Stock	Purchase	$241,200	+90,000	+26%	$2.68	440,000	08 Dec 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.34 to $2.75, inclusive. The reporting person undertakes to provide Exagen Inc., any security holder of Exagen Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this form 4.

Content

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.34 to $2.75, inclusive. The reporting person undertakes to provide Exagen Inc., any security holder of Exagen Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this form 4.